• there has been recent international consensus to rename nonalcoholic fatty liver disease (nafld) to improve awareness and patient identification and reduce stigma;[1] using this. Now a new interdisciplinary european guideline has been published that defines masld as the combination of steatotic liver disease with one or more cardiometabolic risk. The european association for the study of the liver (easl) congress, europe's largest event in hepatology, took place in milan, italy from 5 to 8 june 2024 in a hybrid format.
The presence of masld is. Whether produced alone or in partnership with other organisations, easd statements and guidelines have significant visibility and substantial impact on health care, particularly when.